Cited by 277Liver Disease Diagnosis and TreatmentLiver Diseases and ImmunityLiver Disease and Transplantation

Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials

Open access
Anstee, Quentin M., Lawitz, Eric J., Alkhouri, Naim, Wong, Vincent Wai‐Sun, Romero‐Gomez, Manuel, Okanoue, Takeshi, Trauner, Michael, Kersey, Kathryn +17 more·2019·Hepatology

Abstract

Accurate noninvasive tests (NITs) are needed to replace liver biopsy for identifying advanced fibrosis caused by nonalcoholic steatohepatitis (NASH). We analyzed screening data from two phase 3 trials of selonsertib to assess the ability of NITs to discriminate advanced fibrosis. Centrally read biopsies from the STELLAR studies, which enrolled patients with bridging fibrosis and compensated cirrhosis, were staged according to the NASH Clinical Research Network classification. We explored associations between fibrosis stage and NITs, including the nonalcoholic fatty liver disease fibrosis score (NFS), fibrosis‐4 (FIB‐4) index, Enhanced Liver Fibrosis (ELF) test, and liver stiffness by vibration‐controlled transient elastography (LS by VCTE). The performance of these tests to discriminate advanced fibrosis, either alone or in combinations, was evaluated using areas under the receiver operating characteristic curve (AUROCs) with 5‐fold cross‐validation repeated 100 times. Of the 4,404 patients screened for these trials, 3,202 had evaluable biopsy data: 940 with F0‐F2 fibrosis and 2,262 with F3‐F4 fibrosis. Significant differences between median values of NITs for patients with F0‐F2 versus F3‐F4 fibrosis were observed: −0.972 versus 0.318 for NFS, 1.18 versus 2.20 for FIB‐4, 9.22 versus 10.39 for ELF, and 8.8 versus 16.5 kPa for LS by VCTE (all P < 0.001). AUROCs ranged from 0.75 to 0.80 to discriminate advanced fibrosis. FIB‐4 followed by an LS by VCTE or ELF test in those with indeterminate values (FIB‐4 between 1.3 and 2.67) maintained an acceptable performance while reducing the rate of indeterminate results. Conclusion: Among patients being considered for enrollment into clinical trials, NITs alone or in combination can reduce the need for liver biopsy to discriminate advanced fibrosis caused by NASH. The predictive value of these tests for general screening will require confirmation in a real‐world population.

Integrity signals

Registry

Crossref · 10.1002/hep.30842

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In NAFLD, the threshold for ruling-out/in advanced fibrosis ranges between 9.9 and 11.4 kPa in the STELLAR trials, while a large meta-analysis reported a lower threshold of 7.4 kPa (90% sensitivity) and upper threshold of 12.1 kPa (90% specificity).

    “In the specific etiology of NAFLD, the threshold for ruling‐out/in advanced fibrosis ranges between 9.9 and 11.4 kPa in the STELLAR trials [73] while in a recently published large meta‐analysis a lower threshold of 7.4 kPa (90% Sensitivity) and upper threshold of 12.1 kPa (90% specificity) was published [74].”

    From Current treatment of non‐alcoholic fatty liver disease (2022) · cites this paper as [73]

The citation lists haven’t been fetched yet

References 37 · Cited by 277

Authors
Anstee, Q. M., Lawitz, E. J., Alkhouri, N., Wong, V. W., Romero‐Gomez, M., Okanoue, T., Trauner, M., Kersey, K., Li, G., Han, L., Jia, C., Wang, L., Chen, G., Subramanian, G. M., Myers, R. P., Djedjos, C. S., Kohli, A., Bzowej, N., Younes, Z., Sarin, S., Shiffman, M. L., Harrison, S. A., Afdhal, N. H., Goodman, Z., & Younossi, Z. M.
Affiliations
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • The University of Texas at San Antonio Health Science Center (US)
  • Department of Medicine and Therapeutics,The Chinese Hospital of Hong Kong,Hong Kong
  • Hospital Universitario Virgen del Rocio,Seville,Spain
  • Saiseikai Suita Hospital (JP)
  • Medical University of Vienna (AT)
  • Gilead Sciences (United States) (US)
  • Institute for Liver Health (US)
  • Ochsner Medical Center (US)
  • Gastro One (United States) (US)
  • Bon Secours Liver Institute of Richmond (US)
  • Pinnacle Clinical Research (US)
  • Beth Israel Deaconess Medical Center (US)
  • Inova Fairfax Hospital (US)
Corresponding author
Anstee, Quentin M.
Venue
Hepatology
Published
2019-08-19
Volume
70
Issue
5
Pages
1521-1530
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W2954348899
Cited by
277
References
37
Citations by year
2026: 21 · 2025: 19 · 2024: 34 · 2023: 42 · 2022: 46 · 2021: 64 · 2020: 42 · 2019: 7
FWCI
30.26
Type
journal article
Language
en
Open access
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Topics
  • Health Sciences › Medicine › Epidemiology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
Keywords
nonalcoholic steatohepatitis, advanced liver fibrosis, noninvasive fibrosis assessment, fibrosis staging, FIB-4, enhanced liver fibrosis test, vibration-controlled transient elastography, liver stiffness, selonsertib, STELLAR trial, bridging fibrosis, compensated cirrhosis
MeSH terms
Aged, Biopsy, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Severity of Illness Index, Reproducibility of Results, Clinical Trials, Phase III as Topic, Diagnostic Techniques and Procedures, Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review